Pragmatica-Lung, the first study born from a broader effort by NCI, FDA, industry, academia, and advocacy groups to modernize the clinical trial process, has begun enrolling patients.
NCI has released the language of the much-discussed National Cancer Plan, an eight-goal blueprint that spans the spectrum of cancer care—prevention, treatment, and survivorship—to correspond with President Joe Biden’s vision of cutting cancer mortality by half in 25 years.
Jed Manocherian wants your attention—but not for himself.
Soon after real estate developer and investor Jed Manocherian started a non-profit that lobbies for biomedical research, he heard about the outsized role Mary Lasker played in shaping government-funded biomedical research in the U.S.
Mary Lasker left a collection of detailed oral histories and a massive archive of documents, kept at Columbia University: 795 boxes and 7 flat boxes, which amount to 353 linear feet.
NCI is on the cusp of releasing designs for its National Cancer Plan, an initiative that would guide the institute’s mission and portfolio for years to come and engage everyone in oncology to “end cancer as we know it,” said NCI Director Monica Bertagnolli.
The majority of epithelial ovarian cancer is diagnosed at an advanced stage and long-term survival is low. Since ovarian cancer screening is ineffective, the main focus to reduce ovarian cancer mortality is prevention.
President Joe Biden is requesting a $920 million increase to the NIH budget in fiscal year 2024, a 1.93% boost. Of that amount, $503 million, or nearly 55%, is slated for NCI, keeping funding for the majority of other NIH institutes and centers at FY23 levels.
NCI and Cancer Research UK announced nine new research challenges aimed at tackling some of the most profound problems in cancer research. The global funding opportunity is part of the Cancer Grand Challenges program, an initiative launched by NCI and Cancer Research UK in 2020.
Researchers at NCI Center for Cancer Research have identified extrachromosomal DNA as a major driver of small cell lung cancer, highlighting a novel biomarker and therapeutic target that could be used to eliminate the most aggressive and shapeshifting SCLC cells. The study was published in Cancer Discovery.